Compare with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES STRIDES PHARMA SCIENCE ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x - 8.1 - View Chart
P/BV x 6.7 1.0 687.0% View Chart
Dividend Yield % 0.6 0.5 129.8%  

Financials

 ALKEM LABORATORIES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
STRIDES PHARMA SCIENCE
Mar-18
ALKEM LABORATORIES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs1,5891,147 138.5%   
Low Rs1,232642 191.9%   
Sales per share (Unadj.) Rs417.5317.2 131.6%  
Earnings per share (Unadj.) Rs56.37.8 717.6%  
Cash flow per share (Unadj.) Rs64.725.1 258.3%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.2 402.7%  
Book value per share (Unadj.) Rs292.9274.3 106.8%  
Shares outstanding (eoy) m119.5789.50 133.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.42.8 119.8%   
Avg P/E ratio x25.1114.0 22.0%  
P/CF ratio (eoy) x21.835.7 61.1%  
Price / Book Value ratio x4.83.3 147.6%  
Dividend payout %22.625.5 88.5%   
Avg Mkt Cap Rs m168,65380,058 210.7%   
No. of employees `000NA2.5 0.0%   
Total wages/salary Rs m9,1714,341 211.3%   
Avg. sales/employee Rs ThNM11,325.8-  
Avg. wages/employee Rs ThNM1,731.4-  
Avg. net profit/employee Rs ThNM280.1-  
INCOME DATA
Net Sales Rs m49,91528,394 175.8%  
Other income Rs m1,645941 174.9%   
Total revenues Rs m51,56129,334 175.8%   
Gross profit Rs m8,4823,965 213.9%  
Depreciation Rs m1,0061,540 65.3%   
Interest Rs m6711,962 34.2%   
Profit before tax Rs m8,4511,403 602.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,60697 1,650.6%   
Profit after tax Rs m6,731702 958.7%  
Gross profit margin %17.014.0 121.7%  
Effective tax rate %19.06.9 274.1%   
Net profit margin %13.52.5 545.4%  
BALANCE SHEET DATA
Current assets Rs m27,06224,836 109.0%   
Current liabilities Rs m15,32418,993 80.7%   
Net working cap to sales %23.520.6 114.3%  
Current ratio x1.81.3 135.1%  
Inventory Days Days6771 93.7%  
Debtors Days Days41113 36.4%  
Net fixed assets Rs m12,61034,289 36.8%   
Share capital Rs m239895 26.7%   
"Free" reserves Rs m34,49023,651 145.8%   
Net worth Rs m35,02724,546 142.7%   
Long term debt Rs m1,21215,513 7.8%   
Total assets Rs m54,38765,437 83.1%  
Interest coverage x13.61.7 793.1%   
Debt to equity ratio x00.6 5.5%  
Sales to assets ratio x0.90.4 211.5%   
Return on assets %13.64.1 334.2%  
Return on equity %19.22.9 671.8%  
Return on capital %24.96.9 360.5%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56315,697 41.8%   
Fx outflow Rs m3,012735 409.5%   
Net fx Rs m3,55214,962 23.7%   
CASH FLOW
From Operations Rs m7,2591,871 388.0%  
From Investments Rs m1,8645,826 32.0%  
From Financial Activity Rs m-9,273-10,157 91.3%  
Net Cashflow Rs m-150-2,615 5.7%  

Share Holding

Indian Promoters % 66.9 27.7 241.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 37.8 87.6%  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 25.9 -  
Shareholders   68,381 56,241 121.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   WOCKHARDT  TTK HEALTHCARE  SHASUN PHARMA  BIOCON   FULFORD INDIA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 21 Points Higher; Banking and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets witnessed buying interest during closing hours today and ended their day marginally higher.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Ditch the Risky Fixed Deposits for Safer 'Bluechip Deposits'(Profit Hunter)

Oct 30, 2019

Most people think stocks are riskier than fixed deposits and bonds. The last quarter century proves otherwise.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Nov 11, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS